(Strategic partnership aims to revolutionize downstream bioprocessing with global commercialization rights granted to Sartorius.)
Global life science leader Sartorius has announced a strategic collaboration with Sanofi, a leading biopharmaceutical company, to develop and commercialize a cutting-edge end-to-end Integrated Continuous Bioprocessing (ICB) platform. This landmark partnership is set to transform downstream bioprocessing by enabling seamless integration and continuous processing technologies.
Under the terms of the collaboration and licensing agreement, Sartorius has been selected as Sanofi’s preferred supplier and will leverage its deep engineering and manufacturing expertise to industrialize and scale ICB platforms originally developed as prototypes by Sanofi.
In a significant move, Sanofi will grant Sartorius exclusive global commercialization rights along with access to its proprietary know-how and patent portfolio related to the ICB platform. This will empower Sartorius to bring this next-generation bioprocessing technology to pharmaceutical and biopharmaceutical manufacturers worldwide.
The collaboration underscores a shared commitment to advancing innovative biomanufacturing solutions that enhance efficiency, scalability, and product quality in biologics production. With increasing industry demand for continuous bioprocessing technologies, this alliance places both companies at the forefront of biopharma innovation.
Stay tuned to MediPharma Times for more updates on groundbreaking partnerships and biopharmaceutical advancements.